Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “neutral” rating reaffirmed by Mizuho in a note issued to investors on Thursday. They presently have a $25.00 price target on the specialty pharmaceutical company’s stock. Mizuho’s price objective suggests a potential upside of 55.38% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. TD Securities reiterated a “hold” rating and issued a $38.00 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Wells Fargo & Co. reiterated a “sell” rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Rodman & Renshaw reiterated a “buy” rating and issued a $90.00 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Royal Bank Of Canada decreased their price objective on shares of Valeant Pharmaceuticals International from $35.00 to $29.00 and set a “sector perform” rating for the company in a report on Wednesday. Finally, RBC Capital Markets set a $29.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Wednesday. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average price target of $42.26.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.09 on Thursday. Valeant Pharmaceuticals International has a one year low of $13.77 and a one year high of $119.87. The firm’s market capitalization is $5.59 billion. The firm has a 50-day moving average price of $22.57 and a 200 day moving average price of $25.39.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing the consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 41.02%. The firm earned $2.48 billion during the quarter, compared to analyst estimates of $2.49 billion. During the same quarter in the previous year, the business posted $2.74 EPS. Valeant Pharmaceuticals International’s revenue for the quarter was down 11.0% compared to the same quarter last year. Equities research analysts anticipate that Valeant Pharmaceuticals International will post $6.45 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the company. Riggs Asset Managment Co. Inc. raised its stake in Valeant Pharmaceuticals International by 1.4% in the second quarter. Riggs Asset Managment Co. Inc. now owns 14,044 shares of the specialty pharmaceutical company’s stock valued at $283,000 after buying an additional 200 shares in the last quarter. Capstone Asset Management Co. raised its stake in shares of Valeant Pharmaceuticals International by 1.4% in the third quarter. Capstone Asset Management Co. now owns 26,408 shares of the specialty pharmaceutical company’s stock valued at $648,000 after buying an additional 360 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 402 shares during the period. Allen Investment Management LLC raised its stake in shares of Valeant Pharmaceuticals International by 4.1% in the first quarter. Allen Investment Management LLC now owns 12,411 shares of the specialty pharmaceutical company’s stock valued at $326,000 after buying an additional 493 shares during the period. Finally, Breton Hill Capital Ltd. raised its stake in shares of Valeant Pharmaceuticals International by 3.7% in the second quarter. Breton Hill Capital Ltd. now owns 17,379 shares of the specialty pharmaceutical company’s stock valued at $350,000 after buying an additional 627 shares during the period. Institutional investors own 64.39% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.